Omeros (NASDAQ:OMER - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Wednesday.
A number of other analysts have also recently commented on OMER. RODMAN&RENSHAW upgraded shares of Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a "buy" rating and a $9.00 price target for the company. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Omeros in a research note on Thursday, November 14th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Friday, January 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Omeros currently has a consensus rating of "Moderate Buy" and an average price target of $22.50.
Read Our Latest Stock Analysis on OMER
Omeros Stock Up 2.5 %
OMER traded up $0.19 during trading hours on Wednesday, hitting $7.66. 657,069 shares of the company's stock were exchanged, compared to its average volume of 529,739. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60. The stock's 50-day moving average is $9.04 and its two-hundred day moving average is $7.05. The stock has a market cap of $443.90 million, a price-to-earnings ratio of -3.32 and a beta of 2.03.
Institutional Trading of Omeros
A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company's stock worth $5,318,000 after buying an additional 6,839 shares during the last quarter. State Street Corp lifted its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after buying an additional 3,839 shares during the last quarter. Nomura Holdings Inc. lifted its stake in shares of Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock worth $7,383,000 after buying an additional 430,932 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company's stock worth $1,926,000 after buying an additional 18,454 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in shares of Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company's stock worth $1,610,000 after buying an additional 13,201 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Articles

Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.